Tuesday, July 14, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Phase 2 Ebola Trial Advancing As Expected. Nanoviricides announced that it has received approval from the National Ethics Committee in the Democratic Republic of Congo (DRC) for its Phase 2 clinical trial of NV-387 in Ebola. The next step is the filing of a Clinical Trial Application with ACOREP, the DRC regulatory authority. This meets one of our expected milestones to start of patient treatment during summer 2026.
Two Phase 2 Trials Should Begin In A Matter of Weeks. The approval by the National Ethics Committee was a step in the process of starting clinical trials in the DRC. The company has shipped the clinical supplies of NV-387 and is preparing for a Phase 2 trial in MPox and a separate Phase 2 trial in Ebola. We expect regulatory approvals in the next several weeks to allow both trials to begin treating patients during summer 2026 through fall 2026.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
